EVA PHARMA FOR PHARMACEUTICALS AND MEDICAL APPLIANCES S.A.E

EVA Pharma signed a strategic cooperation agreement with Qiantang District's BioPharma Town in Hangzhou, establishing its eighth global office to focus on pharmaceuticals, vaccines, and biologics R&D.

• Quantoom Biosciences and TechInvention Lifecare have signed an MoU to collaborate on RNA-based vaccine development, aiming to improve accessibility and affordability in India through Quantoom's N-Force toolbox platform. • TechInvention will establish end-to-end mRNA production capabilities at their upcoming EU-GMP facility in Mumbai, with plans to achieve GMP-ready status for Ntensify midi scale production by late 2025. • The partnership extends beyond human health to animal and environmental applications, featuring environmentally sustainable technology with modular, low-carbon-footprint mRNA systems.

• EVA Pharma, DNA Script, and Quantoom Biosciences forge a groundbreaking partnership to develop the first digital-to-biologics mRNA production platform, targeting 100 million vaccine doses annually. • The collaboration integrates enzymatic DNA synthesis, mRNA production, and formulation technologies to accelerate vaccine development from years to weeks, addressing both human and animal health needs. • This initiative supports Africa CDC's goal of 60% local vaccine production by 2040 and Egypt's target of manufacturing 385 million vaccine doses annually by 2030.

The Egyptian Drug Authority has approved Lilly and EVA Pharma's human insulin glargine injection for treating type 1 and type 2 diabetes.